Navigation Links
American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor

BLAUVELT, N.Y., Nov. 19 /PRNewswire/ -- Dr. Mate Hidvegi, inventor of Avemar fermented wheat germ extract, responds to a press release issued on November 17 by Biropharma Kft, discrediting the Hungarian company for making false and self-serving statements about its U.S. competitor American BioSciences.

Dr. Hidvegi stated from his office in Budapest, Hungary:

"The Biropharma claim that research on Avemar does not apply to AveULTRA,, is misleading. Avemar has always been manufactured according to methods which I developed and patented. American BioSciences utilizes processes covered by my most recent pending patent. State of the art technology more precisely controls process times and temperatures creating a better quality fermented wheat germ extract. Independent analysis shows that Avemar made by Biropharma and sold under the brand name Ave(TM) and Avemar made by American BioSciences and sold under the brand name AveULTRA, are virtually identical, confirmed by the technique of HPLC finger printing. Furthermore, independent comparison by biological assays in both cell lines and animal models shows the American BioSciences product has superior effects," he said. According to Dr. Hidvegi, these data are being prepared for publication in a peer-reviewed scientific journal.

AveULTRA, newly introduced by American BioSciences, contains the same amount of Avemar fermented wheat germ actives per daily use packet as Ave and is three times more concentrated, with 99 percent less non-active ingredients and no sugar. AveULTRA supports cell metabolic regulation, promotes immune system modulation, and maintains healthy cellular and humoral (Th1/Th2) immune balance. It promotes optimal NK cell targeting ability and the coordinated response of macrophages, B-cells and T-Cells.

"AveULTRA is a huge improvement over the original Ave," said Cincinnati OB/GYN Maureen Pelletier, MD, CCN. "My patients like the concentrated formula, as well as the improved taste."

For more information, contact Dean Draznin Communications, Inc.

SOURCE American BioSciences

SOURCE American BioSciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. American Heart Association Late-Breaking Clinical Trial Report: New Reversible Antiplatelet Drug no More Effective Than Irreversible One in PCI
2. Viron to Present Data from Phase II Trial at American Heart Association Conference
3. MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
4. Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
5. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
6. Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society
7. American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience
8. American Oriental Bioengineering Announces September Investor Conferences Participation
9. American Scientific Resources To Be Exclusive Seller of Worlds Only FDA Approved Home Needle Destruction Device
10. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
11. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
Post Your Comments:
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... chat discussion at the Piper Jaffray 27th Annual Healthcare ... discussion is scheduled for Wednesday, December 2, at 8:00 ... replay will be available for 14 days after the ... NormartVP, Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that ... and invited investors to participate via webcast. ... 1, 2015 at 11.00 a.m. Eastern Time --> ... 1, 2015 at 11.00 a.m. Eastern Time --> ... NY      Tuesday, December 1, 2015 at 11.00 ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), the ... entry into the automotive market with a comprehensive and ... of consumer electronics human interface innovation. Synaptics, industry-leading touch ... the automotive industry and will be implemented in numerous ... , Japan , and ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
Breaking Biology News(10 mins):